PMID- 29534625
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 18
IP  - 4
DP  - 2018 Apr
TI  - Cetuximab for treating non-small cell lung cancer.
PG  - 483-493
LID - 10.1080/14712598.2018.1452906 [doi]
AB  - Epidermal Growth Factor Receptor (EGFR)-dependent signaling plays a crucial role 
      in epithelial cancer biology, and dictated the development of several targeting 
      agents. The mouse-human chimeric antibody Cetuximab was among the first to be 
      developed. After about two decades of clinical research it has gained a 
      significant place in the management of advanced colorectal and head and neck 
      cancers, whereas its development in non small cell lung cancer (NSCLC) has not 
      led to a place in routine clinical practice, because of marginal clinical benefit 
      despite statistically significant Phase III trials. Recent data from ongoing 
      trials suggest that more careful selection based on molecular markers may 
      identify good responders. Areas covered: In this article, the authors review the 
      literature concerning basic science studies identifying EGFR as a therapeutic 
      target, pharmacological development of Cetuximab, its pharmacodynamics and 
      pharmacokinetics, and clinical trials on Cetuximab in NSCLC, focusing on recent 
      findings on putative predictive biomarkers. Expert opinion: Cetuximab currently 
      has no role in NSCLC treatment outside of research settings. We argue that 
      failure to identify a predictive biomarker early on has hampered its chances to 
      enter routine practice. Although recent research suggests benefit in highly 
      selected patient subsets, its potential impact is severely dampened by lack of 
      regulatory body approval and the emergence of competitors for the same niches.
FAU - Mazzarella, Luca
AU  - Mazzarella L
AD  - a University of Milano, Department of Oncology and Hemato-Oncology, Division of 
      Early Drug Development for Innovative Therapies , European Institute of Oncology 
      , Milano , Italia.
FAU - Guida, Alessandro
AU  - Guida A
AD  - a University of Milano, Department of Oncology and Hemato-Oncology, Division of 
      Early Drug Development for Innovative Therapies , European Institute of Oncology 
      , Milano , Italia.
FAU - Curigliano, Giuseppe
AU  - Curigliano G
AD  - a University of Milano, Department of Oncology and Hemato-Oncology, Division of 
      Early Drug Development for Innovative Therapies , European Institute of Oncology 
      , Milano , Italia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Antineoplastic Agents, Immunological/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/radiotherapy
MH  - Cetuximab/adverse effects/pharmacokinetics/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - ErbB Receptors/immunology/metabolism
MH  - Exanthema/etiology
MH  - Half-Life
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
OTO - NOTNLM
OT  - Cetuximab
OT  - Predictive biomarkers
OT  - combination trials
OT  - non small cell lung cancer
EDAT- 2018/03/15 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/03/15 06:00
PHST- 2018/03/15 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/03/15 06:00 [entrez]
AID - 10.1080/14712598.2018.1452906 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2018 Apr;18(4):483-493. doi: 
      10.1080/14712598.2018.1452906.